Ascletis Pharma starts U.S. Phase I study for ASC36 obesity tablets
Ascletis Pharma Inc. has initiated a U.S. Phase I study for ASC36 oral tablets in obesity.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.